Business
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025
MIAMI, May 6, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"MIAMI, May 6, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. (\"HOPE\"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (\"NRx\" or the \"Company\") (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced that it will host an investor event at the Mar-A-Lago Club in Palm Beach, Florida, on Thursday, May 8, 2025, at the invitation of club members.\n\n \n \n \n \n \n \n\n \nThis discussion is being held to review previously-disclosed strategic initiatives across HOPE and NRx Pharmaceuticals, including expansion plans for the HOPE network of interventional psychiatry clinics and progress across the NRx clinical pipeline. Current investors who wish to attend are invited to contact the Company.\nKey Topics to be Discussed, based on previously disclosed information:\nRecently announced HOPE clinic acquisitions and potential to scale HOPE's interventional psychiatry networkPlans for integration of digital health solutions, including CRM-based technology and telepsychiatry capabilities, to unify clinical operations across the HOPE networkStatus of the New Drug Application (NDA) for NRX-100 (preservative-free IV Ketamine), following FDA's grant of a $4.3 million filing fee waiver, for treating suicidal depressionRecent filing of a patent for preservative-free ketamine (NRX-100). If granted, the patent could provide market exclusivity for NRX-100 into 2045Breakthrough Therapy Designation of NRX-101; currently preparing to file an NDA for Accelerated Approval in patients with bipolar depression and suicidality or akathisiaDr. Jonathan Javitt, MD, MPH, Founder, Chairman and CEO of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics will lead the discussion.\n\"We are excited to continue to meet with our investor community to discuss the significant progress we've made recently,\" said Dr. Javitt. \"Our continued focus on expanding access to innovative treatments and delivering on key regulatory and operational milestones underscores the potential of HOPE and NRx's leadership in mental health innovation.\"\nAbout NRx Pharmaceuticals, Inc.NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. Th...